(MENAFN Editorial) SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:), a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare Conference in New York on Thursday, February 15, 2018 at 9:30 a.m. ET.

A live webcast of the presentation will be available through the investor relations section of the Company's website at . Following the live webcast, an archived replay will be available on the Company's website.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell therapies using its proprietary induced pluripotent stem cell (iPSC) product platform. This platform uniquely enables the single-cell selection of a precisely engineered iPSC clone and the subsequent creation and maintenance of a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for generating homogeneous cell products in quantities that support the treatment of many thousands of patients in an off-the-shelf manner. The Company's immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as other NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies. The Company's immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy to promote immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit .

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200

MENAFN1302201800703653ID1096458441